Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations ...

China: A new study published in BMC Pulmonary Medicine highlights a significant association between elevated blood eosinophil ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

Eosinophils are pro-inflammatory white blood cells thought to protect against parasitic infections, but in excessive numbers they can cause tissue and organ damage, as observed in eosinophilic ...

One in every 10 kids in the United States has asthma, a chronic breathing condition that can affect nearly every part of ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

PIMS launches advanced MICU and introduces Benralizumab therapy for severe asthma patients, improving quality of life.

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, ...

In her latest Mental Elf blog, Dr Fabiana Corsi-Zuelli discusses the differences in immune cell counts in patients with ...

Researchers have identified a previously unknown biological process that causes tissue and organ damage in conditions where ...